Log in

NASDAQ:RGENRepligen Stock Price, Forecast & News

$143.89
-2.37 (-1.62 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$143.41
Now: $143.89
$146.92
50-Day Range
$113.14
MA: $134.88
$158.27
52-Week Range
$72.32
Now: $143.89
$159.97
Volume185,445 shs
Average Volume570,835 shs
Market Capitalization$7.55 billion
P/E Ratio248.09
Dividend YieldN/A
Beta1.14
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell alternating tangential flow systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius tangential flow filters line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH and Sartorius Stedim Biotech to develop multiple affinity ligands. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More
Repligen logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$270.24 million
Cash Flow$1.33 per share
Book Value$20.36 per share

Profitability

Net Income$21.41 million

Miscellaneous

Employees548
Market Cap$7.55 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$143.89
-2.37 (-1.62 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Repligen (NASDAQ:RGEN) Frequently Asked Questions

How has Repligen's stock price been impacted by COVID-19 (Coronavirus)?

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGEN stock has increased by 58.1% and is now trading at $143.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Repligen?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Repligen
.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Repligen
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) posted its earnings results on Thursday, July, 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.28 by $0.14. The biotechnology company had revenue of $87.46 million for the quarter, compared to analyst estimates of $78.11 million. Repligen had a return on equity of 5.93% and a net margin of 10.23%.
View Repligen's earnings history
.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY20 earnings guidance on Thursday, July, 30th. The company provided EPS guidance of $1.24-1.29 for the period, compared to the Thomson Reuters consensus estimate of $1.13. The company issued revenue guidance of $332-340 million, compared to the consensus revenue estimate of $317.06 million.

What price target have analysts set for RGEN?

6 equities research analysts have issued 1 year price objectives for Repligen's shares. Their forecasts range from $110.00 to $151.00. On average, they anticipate Repligen's stock price to reach $136.67 in the next twelve months. This suggests that the stock has a possible downside of 5.0%.
View analysts' price targets for Repligen
.

Has Repligen been receiving favorable news coverage?

Press coverage about RGEN stock has trended neutral on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repligen earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Repligen
.

Are investors shorting Repligen?

Repligen saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 2,520,000 shares, a decrease of 15.7% from the April 15th total of 2,990,000 shares. Based on an average trading volume of 590,000 shares, the short-interest ratio is presently 4.3 days. Approximately 5.3% of the company's shares are short sold.
View Repligen's Short Interest
.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Paypal (PYPL), Vertex Pharmaceuticals (VRTX), Splunk (SPLK), Trade Desk (TTD), Advanced Micro Devices (AMD) and Etsy (ETSY).

Who are Repligen's key executives?

Repligen's management team includes the following people:
  • Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)
  • Mr. Jon K. Snodgres, CFO & Sec. (Age 53)
  • Mr. Steve Curran, VP of Global Operations
  • Ms. Sondra S. Newman, Sr. Director of Investor Relations
  • Mr. Stephen Tingley, VP of Sales

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (13.44%), Vanguard Group Inc. (8.35%), Conestoga Capital Advisors LLC (2.11%), Federated Hermes Inc. (1.30%), Marshall Wace LLP (1.22%) and Bank of America Corp DE (1.15%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen
.

Which institutional investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Vanguard Group Inc., Moody Aldrich Partners LLC, Tygh Capital Management Inc., Driehaus Capital Management LLC, Redwood Investments LLC, and American International Group Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr.
View insider buying and selling activity for Repligen
.

Which institutional investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Point72 Asset Management L.P., Bank of America Corp DE, Marshall Wace LLP, Goldman Sachs Group Inc., Canada Pension Plan Investment Board, Nordea Investment Management AB, and Balyasny Asset Management LLC.
View insider buying and selling activity for Repligen
.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $143.89.

How big of a company is Repligen?

Repligen has a market capitalization of $7.55 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis. Repligen employs 548 workers across the globe.

What is Repligen's official website?

The official website for Repligen is www.repligen.com.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.